← Back to Patent Explorer
US5863984A Expired / Lapsed US ⏱️ 0.0 years remaining

Biostable porous material comprising composite biopolymers

Assignee: Université Laval
•
Filing: 1995-12-01
•
Granted: 1999-01-26
•
Expires: 2015-12-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Biomaterials like collagen can be designed for use as scaffolds for connective tissue reconstruction. It is known that proteins conjugated with PEGs exhibit a decrease in their biodegradation rate and their immunogenicity. Different concentrations and molecular weights of PEGs (PEG-750 and PEG-5000) were conjugated by chemical or irradiation means to collagen materials (films or sponges) which were then investigated by physicochemical assays, collagenase assay, fibroblast cell culture and subcutaneous implantation. PEG-conjugation delayed the degradation by collagenase and preserved a normal fibroblasts morphology and confluency in culture. In vivo, the porous structure of non-modified sponges was collapsed by day 15 with few observable fibroblasts between the collagen fibers. In PEG-modified collagen sponges, the porous structure remained stable for at least 30 days. Cell infiltration was particularly enhanced in PEG-750-conjugated collagen sponges. In conclusion, PEGs conjugated onto collagen sponges stabilize the porous structure without deactivating the biological properties of collagen. These porous composite materials could advantageously function as a scaffold to organize tissue ingrowth. Therefore, the present invention relates to a porous biomaterial whose porosity is stabilized by conjugation to PEG-derivatives. Biopolymers other than collagen may be used in the making of such composite materials.

Inventors

  • 👤 charles J. Doillon
  • 👤 Krystina Pietrucha
  • 👤 Rene C. Gaudreault

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 02:41
CPC Classifications
C; C08; C08H; C08H1/00; C08H1/06; A; A61; A61L; A61L27/00; A61L27/40; A61L27/44; A61L27/48

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 40 words
A biomaterial of a stable porosity which comprises a porous biopolymer matrix into which is impregnated and conjugated a polyethylene molecule having a substituted ether end, which is conjugated to said biopolymer through a reactive group present on said biopolymer.
Claim 2
Dependent Claim 40 words
A biomaterial of a stable porosity which comprises a porous biopolymer matrix into which is impregnated and conjugated a polyethylene molecule having a substituted ether end, which is conjugated to said biopolymer through a reactive group present on said biopolymer.
Claim 3
Dependent Claim 277 words
A biomaterial as defined in claim 1 wherein said polyethylene molecule has the following formula: A--O--(CH.sub.2 --CH.sub.2 --O).sub.m --(CH.sub.2).sub.n --Z wherein: m is an integer comprised between 2 and 500; n is an integer comprised between 1 and 7; A is a substituent represented as a moiety prior to its linkage at its left end to said reactive group of said biopolymer, said moiety being selected from the group consisting of: B--CR═CH--, wherein R is hydrogen or a lower alkyl, and B is hydrogen, carboxy, hydroxy, aldehyde, NH 2 -- or SH--; cyanuric chloride or hydrogen cyanide; 2 OS--X--CH 2 --, wherein X is absent or a linear, branched or aromatic group of 1 to 6 carbon atoms; D--OOC--(CH 2 ) o --, wherein o is an integer comprised between 1 to 7, and D is, hydrogen, an anhydride, a mixed anhydride or an activated ester of 1 to 8 carbon atoms; --N--(CH 2 ) o --, wherein o is an integer comprised between 1 to 7; --S--(CH 2 ) o , wherein o is an integer comprised between 1 to 7; --Z is selected from the group consisting of: hydrogen; --FGE wherein F is O - , N - or S - , G is hydrogen, a lower alkyl, a cycloalkyl of 1 to 7 carbon atoms or --C(O)--I, wherein I is a reactive group of a pharmaceutical agent, and E is absent hydrogen or a lower alkyl; and --C(O)--JE, wherein J is hydrogen, a lower alkyl, a cycloalkyl of 1 to 7 carbon atoms or --O--K, wherein K is a reactive group of a pharmaceutical agent, and E is absent hydrogen or a lower alkyl.
Claim 4
Dependent Claim 28 words
A material according to claim 1 wherein said biopolymer is selected from collagen, crosslinked gelatin, fibronectin, larninin, vitronectin, fibrinogen/fibrin, glycosaminoglycans, Matrigel™ basement membrane matrix, cellulose, chitosan and chitin.
Claim 5
Dependent Claim 25 words
A material according to claim 2 wherein said biopolymer is selected from collagen, crosslinked gelatin, fibronectin, laminin, vitronectin, fibrinogen/fibrin, glycosaminoglycans, Matrigel™ cellulose, chitosan and chitin.
Claim 6
Dependent Claim 11 words
A material according to claim 3 wherein said biopolymer is collagen.
Claim 7
Dependent Claim 11 words
A material according to claim 4 wherein said biopolymer is collagen.
Claim 8
Dependent Claim 13 words
A material according to claim 5 wherein said biopolymer is type I collagen.
Claim 9
Dependent Claim 13 words
A material according to claim 6 wherein said biopolymer is type I collagen.
Claim 10
Dependent Claim 12 words
A material according to claim 2 wherein A is acrylate or methacrylate.
Claim 11
Dependent Claim 12 words
A material according to claim 3 wherein A is acrylate or methacrylate.
Claim 12
Dependent Claim 12 words
A material according to claim 6 wherein A is acrylate or methacrylate.
Claim 13
Dependent Claim 17 words
A material according to claim 9, 10 or 11, wherein said conjugation is performed by gamma radiation.
Claim 14
Dependent Claim 14 words
A material according to claim 2 wherein said pharmaceutical agent is a growth factor.
Claim 15
Dependent Claim 36 words
A material according to claim 13 wherein said growth factor is selected from the group consisting of: FGF, EGF, TGF, PDGF, TNF, IGF, CSF, NGF, heparin binding growth factor, interferons, erythropoeitin, interleukins and tissue activating peptides.
Claim 16
Dependent Claim 30 words
A material according to claim 2, 4 or 6 wherein A is cyanuric chloride, m is an integer comprised between 7 to 45, n is 1 and Z is hydrogen.
Claim 17
Dependent Claim 38 words
A material according to claim 2, 4 or 6 wherein A is D--O(O)C--(CH 2 ) 3-5 wherein D is hydrogen, or succinimidyl, m is an integer comprised between 7 to 45, n is 1 and Z is hydrogen.

References Cited (Backward Citations)

US4179337A Cited
US4101380A Cited
US4970298A Cited
US4840851A Cited
US4904708A Cited
US4871490A Cited
US5290548A Cited
US5162430A Cited
WO1993013753A1 Cited
EP0568334A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2002-01-25 2002-07-27 2003-01-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2006-01-25 2006-07-27 2007-01-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2010-01-25 2010-07-27 2011-01-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag